Vepugratinib

Vepugratinib is a small-molecule drug developed by Eli Lilly and. The sponsor describes its target as FGFR3, which OnCo does not yet have a target page for. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07218380 (A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract), in bladder & urothelial cancer. The largest, NCT07218380, plans to enrol 450 participants with primary completion expected 2029-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.